- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Launches AccessGUDID, a Database to Track Devices
The database will allow consumers, healthcare providers, and product manufacturers to access information tracked on medical devices, with the end goal of improving patient safety, improving device postmarket surveillance, and facilitating medical device innovation.
The FDA launched an eagerly-anticipated database to allow consumers, healthcare providers and product manufacturers to access information tracked on medical devices.
The online Global Unique Device Identification Database, called AccessGUDID, follows almost 3 years after Congress mandated that medical devices be marked and tracked with unique identifiers. FDA’s database uses a unique device identification system to identify devices sold in the US, with the capability to track them from manufacturing through distribution to patient use, the FDA said.
When fully implemented, the label of most devices will include a UDI in human- and machine-readable form. Device labelers must also submit certain information about each device to AccessGUDID, where the public can search and download information.
Read the article on Governement HealthIT: http://bit.ly/1ctcAlM
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
October 21st 2024Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.
Read More
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
